The company’s products include EYLEA injection to treat wet age-related ... inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic ...

The US Food and Drug Administration (FDA) has announced it has approved colon cancer drug, Zaltrap, for use in combination with a folinic acid, fluorouracil and iriontecan (FOLFIRI) chemotherapy ...

The company has successfully developed several blockbuster medicines, including Eylea and Eylea HD for retinal diseases (such as wet age-related macular degeneration, diabetic macular edema ...

The company said this morning that the COAST trial of sozinibercept (OPT-302) as a combination therapy with blockbuster wet AMD therapy Regeneron/Bayer's Eylea (aflibercept) wasn't able to show ...

In 2025 to 2026, we anticipate sustained growth in revenues from our product launches worldwide from the proposed biosimilars for Prolia, Xgeva, Simponi and Simponi Aria, and Eylea low dose ...

Strategic initiatives include launching biosimilars for Prolia, Symphony, and EYLEA, and exploring a potential listing on the Stockholm Exchange.

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against ...

Ultra-low-power cryogenic complementary metal oxide semiconductor (cCMOS) technology is crucial for quantum computers. This Perspective highlights the challenges of the state-of-the-art technology ...